Global Finance News
19 Mar 2026, 19:04
Johnson & Johnson announced that the U.S. FDA has approved ICOTYDE (icotrokinra), a first-in-class oral IL-23 receptor antagonist for the treatment of moderate-to-severe plaque psoriasis in patients aged 12 and older . The drug is the first targeted oral peptide in its class, offering a once-daily systemic treatment option.
The approval is based on Phase 3 data showing strong efficacy and safety, with around 70% of patients achieving clear or nearly clear skin and more than half reaching significant disease reduction (PASI 90) at 16 weeks. Safety results were comparable to placebo, with no new safety concerns identified.
The launch positions ICOTYDE as a potential first-line systemic therapy, addressing unmet needs for patients who do not respond adequately to topical treatments and marking a shift toward more convenient, oral-based treatment approaches in psoriasis care.
PRNewswire
The approval is based on Phase 3 data showing strong efficacy and safety, with around 70% of patients achieving clear or nearly clear skin and more than half reaching significant disease reduction (PASI 90) at 16 weeks. Safety results were comparable to placebo, with no new safety concerns identified.
The launch positions ICOTYDE as a potential first-line systemic therapy, addressing unmet needs for patients who do not respond adequately to topical treatments and marking a shift toward more convenient, oral-based treatment approaches in psoriasis care.
PRNewswire